Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sparsentan vs irbesartan in primary focal segmental glomerulosclerosis
2016-005141-23Phase 3Unknown
- Sponsor
- Travere Therapeutics
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sparsentan in focal segmental glomerulosclerosis (FSGS) (2 arms), sponsored by Travere Therapeutics. Status: unknown.
02
Drugs
sparsentan
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2016-005141-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005141-23.